ReviewTropical medicine and health2026
Quantitative total serum IgG4 reporting in human paragonimiasis: a scoping review.
Review in Tropical medicine and health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundParagonimiasis is a food-borne parasitic disease caused by lung flukes belonging to the genus Paragonimus. It can produce pulmonary, pleural, and other organ manifestations that overlap clinically, radiologically, and histopathologically with malignancy, tuberculosis, and immune-mediated disorders. Elevated total serum immunoglobulin G4 (IgG4) concentrations and IgG4-positive plasma cell infiltration may mimic IgG4-related disease (IgG4-RD), but quantitative serum IgG4 levels in paragonimiasis have not been systematically characterized.
methodsWe conducted a multi-database scoping review of human paragonimiasis case reports and case series published from January 1, 1965, to December 31, 2025. PubMed, Ichushi-Web, Chinese National Knowledge Infrastructure (CNKI), and KoreaMed were searched using database-specific strategies, supplemented by multilingual Google Scholar checks. The review was reported in accordance with the PRISMA-ScR checklist.
resultsAmong 610 reports comprising 886 cases, quantitative serum IgG4 values were reported in 10 reports (1.6%) and 12 cases (1.4%). The countries of first-author affiliation were Japan (n = 6), China (n = 2), Thailand (n = 1), and France (n = 1), and all reports were published in 2012 or later. The 12 cases included pulmonary, pleural/intrathoracic, pericardial, central nervous system, and adrenal presentations. Among the 11 cases reported in mass concentration units, serum IgG4 values ranged from 94.1 to 3,350 mg/dL, and 10 values were elevated. The remaining case was reported as elevated (1,990 IU/mL) but was not converted to mass concentration units. Tissue pathology was described in 8 cases, and IgG4-positive plasma cell infiltration, IgG4-positive inflammation, or an increased tissue IgG4/IgG ratio was reported in 4 cases. None of the pathology reports described storiform fibrosis or obliterative phlebitis, which are hallmarks of IgG4-RD. Based on the information available in the original publications, none of the 12 cases were mapped as probable or definite IgG4-RD.
conclusionQuantitative serum IgG4 values are rarely reported in paragonimiasis case literature, and selective testing and reporting precluded estimation of the prevalence of serum IgG4 elevation. Serum IgG4 elevation and IgG4-positive plasma cells should be interpreted together with exposure history, parasite-directed evidence, and histopathology. Early consideration of paragonimiasis may prevent delayed diagnosis and inappropriate immunosuppression owing to misdiagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.